

Special Issue

Intensive Care during COVID-19 Pandemic

Message from the Guest Editors

The coronavirus disease 2019 (COVID-19) pandemic has placed an unprecedented demand on modern healthcare resources, particularly with the sudden increase in the need for intensive care for pneumonia with multiorgan disease. As such, it is necessary to predict which patients with oxygen issues will be able to avoid mechanical ventilation. Such patients can be safely cared for in other parts of the hospital, thus preserving intensive care unit capacity for mechanically ventilated patients. Based on your extensive knowledge and experience, we invite you to provide an original report, original observation, or review to highlight (i) care, treatment, protection, and clinical outcomes of patients in intensive care during COVID-19, both COVID-19 patients and non-COVID-19 patients; (ii) prognostic factors, comorbidities, and epidemiological characteristics of patients in intensive care for COVID-19, especially among vaccinated patients; (iii) strategies and theoretical basis for the hierarchical management of wards in patients with multiple organ disease; and (iv) the latest development of novel preventive and therapeutic vaccines.

Guest Editors

Dr. Haiyan Yang

Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, China

Dr. Yuefei Jin

Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, China

Deadline for manuscript submissions

closed (31 October 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/130859

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).